Grant of Share Options

Immupharma PLC

19 March 2024

 

                                                                                                                                                                         19 March 2024

ImmuPharma PLC

("ImmuPharma" or the "Company")

  Grant of Share Options

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.

The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting  conditions which reflect the corporate objective of restoring and enhancing shareholder value as follows:

Tim McCarthy                    8,000,000 share options (exercise price £0.02)

Tim Franklin                       6,500,000 share options (exercise price £0.02)

Sebastien Goudreau         5,000,000 share options (exercise price £0.02)

In addition, 5,500,000 unapproved Share Options have been awarded to other employees/contractors with the same performance conditions.

Share Option Period: All Share Options are valid for 10 years from the date of issue.

Time and Performance Conditions:

All Share Options will vest at the latter of:

·    When the Company has completed a new commercial deal of significant value; and

·    3 years from the date of issue

The Remuneration Committee will determine when these conditions have been met.

ENDS

For further information please contact: ImmuPharma PLC (www.immupharma.com) Tim McCarthy, Chief Executive Officer Lisa Baderoon, Head of Investor Relations [phone] + 44 (0) 7721 413496 SPARK Advisory Partners Limited (NOMAD) Neil Baldwin Stanford Capital Partners (Joint Broker) Patrick Claridge,  Bob Pountney SI Capital (Joint Broker) Nick Emerson [phone] [phone] [phone]

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tim McCarthy
2	Reason for the notification
a)	Position/status	Chairman and Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1p each ISIN: GB0033711010
b)	Nature of the transaction	Grant of share options over new Ordinary Shares
c)	Price(s) and volume(s)	Exercise Price	Volume
		2 pence	8,000,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	18 March 2024
f)	Place of the transaction	n/a

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Tim Franklin
2	Reason for the notification
a)	Position/status	Chief Operating Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1p each ISIN: GB0033711010
b)	Nature of the transaction	Grant of share options over new Ordinary Shares
c)	Price(s) and volume(s)	Exercise Price	Volume
		2 pence	6,500,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	18 March 2024
f)	Place of the transaction	n/a

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sebastien Goudreau
2	Reason for the notification
a)	Position/status	Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ImmuPharma PLC
b)	LEI	213800VZKGHXC7VUS895
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of 1p each ISIN: GB0033711010
b)	Nature of the transaction	Grant of share options over new Ordinary Shares
c)	Price(s) and volume(s)	Exercise Price	Volume
		2 pence	5,000,000
d)	Aggregated information - Aggregated volume - Price	N/A
e)	Date of the transaction	18 March 2024
f)	Place of the transaction	n/a

 

END